Advocates Say Women With PMOS Should Get Subsidised Weight-Loss Drugs
The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia is pushing for GLP-1 medications to be listed on the Pharmaceutical Benefits Scheme.
Written by EGazette’s AI. The facts are drawn from cited sources; the analysis is the AI’s own.
Advocates say women living with PMOS, a chronic hormonal condition, should have access to taxpayer-funded weight-loss medications, according to the Guardian.
The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging the government to approve GLP-1 drugs on the Pharmaceutical Benefits Scheme for people living with the condition.
Currently, GLP-1 medications used to treat the condition are not specifically approved by Australia's Therapeutic Goods Administration (TGA) for that purpose, meaning patients are being prescribed them off-label.
Advocates argue that subsidising the drugs would improve access for patients who currently face high out-of-pocket costs for off-label treatment.
The government has not yet responded publicly to the advocacy group's call for the medications to be added to the subsidised scheme.
Sources
- Women with PMOS should get subsidised weight-loss drugs, Australian advocates say — The Guardian — World
EGazette summarizes reporting from multiple sources; follow the links for the originals.
Comments
Loading comments…
Related articles
Ebola outbreak worsening in eastern DR Congo, NGO warns
North Kivu province accounts for nearly 40% of the country's new confirmed Ebola cases, according to the report.
Russia Dismisses Reports of Second Plague Case as 'False Information'
Moscow has rejected claims of a second pneumonic plague case, as a senior WHO official calls for Russia to share more details on the suspected cases.
Gaza doctors say child developed autoimmune condition amid war conditions
Health workers in Gaza report a child has developed an autoimmune condition, which they attribute to the strain the war has placed on health and living conditions in the territory.
What we don't know about gray-market peptides like BPC-157 is the real risk, Verge column argues
In her Optimizer newsletter, Verge senior reviewer Victoria Song argues that the biggest danger of gray-market peptides is the lack of reliable data on how they're actually used.
Abortion pill access jumps almost 50% after Australia eases pharmacy restrictions
A new study finds the number of Australian pharmacies stocking an abortion medication nearly doubled since prescribing rules were relaxed in 2023.
Ukraine's foreign ministry sees no current threat from possible plague outbreak in Russia
Ukraine's Ministry of Foreign Affairs says there is currently no danger to the country from a possible plague emergence in Russia.